Lancet Oncology Formatting Requirements: Complete Author Guide

Lancet Oncology requires a semistructured summary for Articles, not exceeding 300 words. The required headings are:

• Background

• Methods

• Findings (not "Results")

• Interpretation (not "Conclusions")

• Funding

Two things to note here. First, Lancet Oncology uses "Findings" instead of "Results" and "Interpretation" instead of "Conclusions." Use the five headings the information for authors specifies. Second, the Funding section is part of the abstract itself, not a separate element. Name all funding sources in a single sentence at the end of the abstract.

The Background section should be 1-2 sentences establishing the rationale. Don't open with "Cancer is a leading cause of death worldwide" or similar generic statements. Get straight to the specific question.

The Methods section should cover study design, setting, participants, interventions, and primary endpoint in concise terms. For clinical trials, include the trial registration number here.

Findings must include specific numerical results: hazard ratios, confidence intervals, P values, and response rates for primary and key secondary endpoints. Lancet Oncology reviewers expect to evaluate the data from the abstract alone.

Interpretation should be 2-3 sentences that put your findings in clinical context. What do these results mean for patients? Don't overstate or suggest practice changes that your data don't directly support.

This is the most distinctive formatting element of Lancet journals, and it's mandatory for all Articles. The Research in Context panel is a structured box with three sections:

Evidence before this study: Describe the systematic search you conducted to identify existing evidence. Include databases searched, search terms, date range, and language restrictions. Summarize what was known before your study.

Added value of this study: Explain what your study contributes beyond existing evidence. Be specific about the novelty.

Implications of all the available evidence: Discuss what the totality of evidence (including your study) means for clinical practice, policy, or future research.

The Research in Context panel should not contain references, and it must be substantive. Lancet editors take this seriously. A vague or poorly researched Evidence before this study section will draw criticism. You need to show that you actually conducted a systematic search, not just cited papers you already knew about.

The title page must include:

• A brief title

• All author names with preferred degree (one only), affiliations, and full addresses

• The corresponding author's name and address, with email and telephone details

Each author's specific contributions must be described at the end of the manuscript. More than one author must have directly accessed and verified the underlying data, and all authors should confirm they had full access to all the data in the study and accept responsibility to submit for publication.

The Lancet Oncology information for authors publishes no limit on figures and tables for Articles. The Lancet general Article template says, as a guide, 3 to 6 tables and figures.

Figure requirements:

• Photographs and photographic images: no less than 300 dpi at final printed size, and digital photography files at least 107 mm wide

• Ideal formats for photographs: TIF or JPG

• Illustrations: editable vector files with selectable geometry and fonts, such as Adobe Illustrator (.ai), .eps, vector-based PDF, PowerPoint, Word, or SVG files

• Trial profiles, study profiles, and CONSORT diagrams: an editable flow diagram in Word or PowerPoint

• Annotated figures: supply one annotated copy and one non-annotated, editable copy

• Each figure uploaded separately

Table requirements:

• Supplied in a separate Word document from the main text, with editable text and all grid lines visible

• No merged cells, except where required in column headings, and no multi-part tables

• Abbreviations spelled out and listed in the table footnotes

• P values to two significant figures, capped at four decimal places

For clinical trial reports, Kaplan-Meier survival data must include numbers at risk at each timepoint. Forest plots should show individual and pooled effect estimates with confidence intervals. These are standard expectations but frequently done incorrectly.

Lancet Oncology uses the Lancet reference style, a numbered format based on Vancouver conventions with some specific differences.

Key formatting rules:

• Superscript citation numbers in text, placed after punctuation

• List all authors up to 6; for 7 or more, list the first 3 followed by "et al"

• Journal titles abbreviated per NLM/Medline conventions

• Use italics for journal titles

• Include volume and page range, but not issue number

• No period after journal abbreviation

Example reference:

1 Smith AB, Jones CD, Williams EF, et al. Immunotherapy combinations in advanced melanoma: a phase 3 randomized trial. Lancet Oncol 2025; 26: 312-20.

Note the formatting specifics: italicized journal title, bold volume number, shortened final page number (312-20, not 312-320), and a space after the semicolon that follows the year. These details differ from standard Vancouver style and will be flagged if incorrect.

The Lancet group's formatting guidelines ask authors to remove EndNote or other referencing software fields before submission. Make sure you're using the Lancet-specific style, not generic Vancouver.

Supplementary material is submitted as one PDF with a table of contents and numbered pages. It is peer reviewed, and it is published at the discretion of the journal's editors.

The appendix can include:

• Additional figures and tables

• Extended methods (including full statistical analysis plans)

• Trial protocols (the information for authors encourages a copy of the study protocol for clinical trials)

• CONSORT/PRISMA flow diagrams (if not in main text)

• Additional subgroup analyses

• Sensitivity analyses

Reports of trials should be submitted with a full protocol in English, or with the full protocol and a synopsis in English. All accepted Articles should include a link to the full study protocol published on the authors' institutional website.

References cited only in the supplementary material are numbered in order of mention there and numbered separately from the references in the full paper.

The Lancet group's formatting guidelines ask for text and tables in a Word document and figures as editable files.

Word submissions:

• Any font and point size (the information for authors says not to worry about type of font or point size)

• Line numbers in the manuscript (the Lancet Article templates include this in their checklist)

• Page numbering (the information for authors says to use page numbering)

LaTeX submissions:

• The Lancet group's formatting guidelines do not describe a LaTeX route; check with the editorial office before submitting in another format

For oncology manuscripts, Word is almost always the right choice. Clinical trial reports, observational studies, and translational research papers don't typically require the mathematical typesetting that makes LaTeX valuable. Save yourself the hassle and submit in Word.

Lancet Oncology has formatting and policy elements that set it apart from other oncology journals. These are the ones that most commonly trip up first-time submitters.

1. Research in Context is non-negotiable. The panel must demonstrate a genuine systematic search, not just a narrative summary of papers you know. Reviewers and editors evaluate the quality of your search strategy.

2. "Findings" and "Interpretation," not "Results" and "Conclusions." The information for authors specifies five summary paragraphs: Background, Methods, Findings, Interpretation, and Funding.

3. Protocol submission for trials. The full trial protocol must be submitted with reports of trials, in English, or the full protocol with a synopsis in English. A statistical analysis plan should be submitted with the protocol if there is one. If your protocol is proprietary, discuss access arrangements with the editorial office before submission.

4. Statistical review and raw data. Research papers are peer reviewed by at least two reviewers and a statistician, and authors may be required to provide the raw data while the paper is under review and for up to 10 years after publication.

5. No presubmission enquiry for a finished manuscript. The information for authors says that in almost all cases, if you have a finished manuscript, you should submit it rather than contact the journal to ask whether an unseen manuscript is likely to be accepted. For a Personal View or Policy Review, contact the Editor before submitting.

Formatting mistakes to avoid, based on the requirements above:

• Missing Research in Context panel

• Using "Results/Conclusions" instead of "Findings/Interpretation" in the abstract

• Exceeding the 3,500-word limit (4,500 for randomised controlled trials) or the 30-reference limit

• Missing full trial protocol for reports of trials

• Reports of trials that do not conform to CONSORT 2025, or meta-analyses that do not follow PRISMA

• Funding not listed within the abstract

• Contributor statement missing or incomplete

For Lancet Oncology-targeted manuscripts, three patterns consistently predict formatting desk-screen failure at The Lancet Oncology. The patterns below are the same ones the journal's handling editors and outside reviewers flag at first-pass triage.

Scope-fit ambiguity in the abstract. Lancet Oncology editors move fastest on manuscripts whose contribution is obviously aligned with practice-changing oncology research. The named failure pattern: preclinical-only oncology papers without clinical-translation pathway get desk-rejected quickly, because the journal communicates in-house decisions quickly. Check whether your abstract reads to Lancet Oncology's scope

Methods package incomplete for the journal's reviewer pool. Lancet Oncology reviewers expect specific methodological detail. Trials missing the explicit pre-specified primary-endpoint extend revision rounds. Check if your methods package is reviewer-complete

Reference-list and clean-citation failure mode. A reference list that includes retracted papers is an avoidable risk. Check whether your reference list is clean against Crossref + Retraction Watch

Manusights submission-corpus signal for The Lancet Oncology. Of the manuscripts our team screened before submission to Lancet Oncology and peer venues in 2025, the editorial-culture mismatch most consistent across the cohort is lancet oncology editors enforce practice-changing threshold; preclinical-only papers without explicit clinical-translation pathway get desk-rejected. In our analysis of anonymized Lancet Oncology-targeted submissions,

For manuscripts targeting Lancet Oncology, four patterns generate the most consistent desk-rejection outcomes.

Trial abstract not structured or exceeding the word limit. Lancet Oncology requires a semistructured summary of no more than 300 words, with Background, Methods, Findings, Interpretation, and Funding paragraphs. The journal specifies "Findings" and "Interpretation," not "Results" and "Conclusion." This signals to editors whether the author team is familiar with Lancet Group formatting standards.

Reports of randomized trials that do not conform to CONSORT 2025. Lancet Oncology says reports of trials must conform to CONSORT 2025, and the Lancet group's RCT formatting guidelines say all reports of randomised trials should include a trial profile, a table of baseline characteristics, and a panel that puts their results into context with previous work.

Research in context panel absent or not formatted to Lancet standards. Lancet Oncology requires a Research in context panel for all primary research Articles, with three sections: Evidence before this study, Added value of this study, and Implications of all the available evidence. It is a distinct requirement from the summary, and the panel should not contain references.

Scope misalignment: the oncology application is secondary to the basic mechanism. Lancet Oncology editors evaluate whether the clinical oncology application is the primary contribution. Submissions where the mechanistic finding is the central result, with clinical data presented as proof-of-concept or preliminary validation, are redirected to journals with a more translational or basic science focus. The information for authors says Lancet Oncology prioritises reports of original research that are likely to change clinical practice or thinking about oncology.

A Lancet Oncology formatting and readiness check evaluates manuscript structure, trial reporting documentation, and scope alignment against these desk-rejection patterns before you submit.

Or see example reports before you finalize.